Akeso
Akeso, Inc., a leading biopharmaceutical company headquartered in China (CN), is renowned for its innovative approach in the fields of oncology and autoimmune diseases. Founded in 2007, Akeso has rapidly established itself as a key player in the biopharma industry, with a strong focus on the research, development, and commercialisation of monoclonal antibodies and bispecific antibodies. With major operational regions across Asia and expanding into global markets, Akeso's core products include its proprietary therapies that target various cancers and immune disorders. The company is distinguished by its commitment to advancing biologics, leveraging cutting-edge technology to enhance treatment efficacy. Notably, Akeso has achieved significant milestones, including successful clinical trials and partnerships that bolster its market position, making it a formidable contender in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Akeso's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso's score of 26 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akeso's reported carbon emissions
In 2023, Akeso reported total carbon emissions of approximately 28,229,430 kg CO2e, with Scope 1 emissions at about 1,397,580 kg CO2e and Scope 2 emissions at approximately 26,831,850 kg CO2e. This represents a significant increase from 2022, where total emissions were about 23,740,020 kg CO2e, with Scope 1 at approximately 82,000 kg CO2e and Scope 2 at around 23,658,020 kg CO2e. In 2021, Akeso's emissions were approximately 4,530,880 kg CO2e, with Scope 1 emissions at about 35,230 kg CO2e and Scope 2 at approximately 4,495,650 kg CO2e. The data indicates a trend of increasing emissions over the years, particularly in Scope 2. Despite the lack of specific reduction targets or climate pledges, Akeso's emissions data highlights the company's ongoing commitment to monitoring and reporting its carbon footprint. The absence of defined reduction initiatives suggests a potential area for future focus as the company navigates its climate responsibilities.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 35,230 | 00,000 | 0,000,000 |
| Scope 2 | 4,495,650 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
